SAN DIEGO (AP) ¿ Diagnostic test maker Sequenom Inc. said late Wednesday its first-quarter loss widened on higher expenses due to research and development spending. The company lost $17.5 million, or 29 cents per share, compared with a loss of $8.6 million, or 19 cents per share, during the same period a year prior. Revenue fell 18 percent to $8.7 million from $10.6 million. Analysts polled by Thomson Reuters expected a loss of 23 cents per share on revenue of $11.2 million. Sequenom's expenses rose 41 percent to $26.5 million, mainly on research and development costs. Meanwhile, consumable revenue remained nearly flat at $4.7 million while system related revenue fell 31 percent to $3.1 million. Services revenue fell 38 percent to $837.000. The company had been preparing to launch the Down syndrome test SEQureDx in June, but will delay because of employee mishandling of test data and results.
More from Technology
Nvidia Reports Earnings on Thursday: 5 Important Things to Watch
Cloud demand trends, gaming GPU sales and Mellanox deal commentary are among the things to watch as Nvidia reports.